SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today the publication of data from preclinical studies performed in collaboration with scientists at Beth Israel Deaconess Medical Center (BIDMC), which demonstrated a 77-fold increase in dendritic cells at the site of administration of a DNA vaccine delivered with electroporation compared to a similar amount of DNA delivered using a DNA injection alone. The paper, “Recruitment of Antigen-Presenting Cells to the Site of Inoculation and Augmentation of HIV-1 DNA Vaccine Immunogenicity by In Vivo Electroporation”, was published online ahead of print at the Journal’s web site http://jvi.asm.org/ on March 19, 2008. This result suggests that electroporation provides a strong adjuvant effect capable of priming the immune system, partially explaining the apparent enhancement that electroporation has provided in enhancing the potency of DNA vaccines in humans.
